Alkem Laboratories Limited

ALKEM IB

ALKEM IBAlkem Laboratories Limited

BSE INDIA

5,098.05

INR

+4.45

(+0.09%)

150.19EPS Dil.

33.94P/E

611.77BMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Alkem Laboratories Limited

ALKEM:IB

(BSE INDIA)

Recent

price

5,098.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 06/14

Stock

S&P500

2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
112.39	136.49	163.36	193.86	225.94	311.4	414.64	469.72	528.1	607.69	685.15	730.01	879.19	970.12	- -	1,059.45	Revenue per Share
19.66	27.61	35.58	41.49	37.14	32.75	56.3	74.61	52.77	63.61	94.26	132.57	137.63	82.31	- -	150.19	Basic EPS, GAAP
-9.38	65.48	-7.59	28.11	-1.4	15.67	39.2	-23	-34.09	20.76	18.57	89.49	64.58	121.24	- -	- -	Free Cash Flow per Basic Share
1.46	1.75	1.75	4.32	2.66	4.74	15.43	7.22	18.2	18.28	36.76	28	35.29	44.29	- -	- -	Dividend per Share
8.76	21.52	38.05	1	1	98.7	144	209.57	242.74	288.23	346.29	450.86	553.49	591.8	591.8	2	Book Value per Share
100.8	125.91	159.23	197	233	224.4	266.76	349.62	382.64	430.49	477.33	585.37	688.55	747.91	856.44	856.44	Tangible Book Value per Share
120	120	120	120	120	120	120	120	120	120	120	120	120	120	- -	120	Basic Weighted Avg Shares
13,439	16,321	19,534	23,181	27,017	37,233	49,577	56,162	63,142	72,658	81,920	87,284	105,120	115,993	126,676	126,676	Sales/Revenue/Turnover
14.58	17.35	19.4	18.49	13.72	10.06	15.55	16.22	14.23	13.05	15.54	19.15	16.68	11.2	15.36	15.36	Operating Margin (%)
234	270	279	360	427	709	1,006	1,012	1,430	1,932	2,528	2,746	3,040	3,104	2,993	2,993	Depreciation Expense
2,351	3,301	4,255	4,961	4,441	3,916	6,731	8,920	6,309	7,605	11,271	15,850	16,456	9,842	17,958	17,958	Net Income, GAAP
4.09	7.07	6.36	2.7	2.42	13.14	19	6.22	31.05	18.96	8.77	12.18	8.89	22.84	10.46	10.46	Effective Tax Rate (%)
17.49	20.22	21.78	21.4	16.44	10.52	13.58	15.88	9.99	10.47	13.76	18.16	15.65	8.48	14.18	14.18	Profit Margin (%)
8,849	17,270	10,985	11,930	9,090	3,321	11,738	12,383	15,319	20,259	22,527	33,248	36,301	50,225	64,170	64,170	Working Capital
695	7,317	1,272	923	539	386	1,235	2,088	1,307	2,313	1,592	342	758	703	2,293	2,293	LT Debt
12,053	15,078	19,055	23,739	27,900	30,847	35,992	45,829	49,853	55,720	63,090	75,580	88,473	94,350	107,144	107,144	Total Equity
- -	12.59	12.65	13.22	9.87	8.01	14.42	17.99	11.05	12.34	16	16.98	15.4	8.99	15.15	15.15	Return on Invested Capital (%)
- -	37.16	32.58	45.56	47.28	25.94	28.26	31.82	18.03	18.44	21.92	23.97	19.63	11.38	21.18	35.13	Return on Capital (%)
- -	182.31	119.46	212.49	3,714.33	65.7	46.39	42.2	23.33	23.96	29.71	33.26	27.41	14.37	25.38	50.59	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	17.1%	11.86%	9.21%
Net Income, GAAP	21.88%	26.99%	82.47%
Free Cash Flow	-89.13%	89.56%	16.5%
Total Cash Common Dividend	53.36%	26.17%	2.07%
Total Equity	14.54%	14.06%	13.56%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India.

Year	Q1	Q2	Q3	Q4	FY
2022	39.15	45.52	43.96	9	137.63
2023	10.68	27.67	38.03	5.94	82.31
2024	23.98	51.9	49.76	24.55	- -

2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
112.39	136.49	163.36	193.86	225.94	311.4	414.64	469.72	528.1	607.69	685.15	730.01	879.19	970.12	- -	1,059.45	Revenue per Share
19.66	27.61	35.58	41.49	37.14	32.75	56.3	74.61	52.77	63.61	94.26	132.57	137.63	82.31	- -	150.19	Basic EPS, GAAP
-9.38	65.48	-7.59	28.11	-1.4	15.67	39.2	-23	-34.09	20.76	18.57	89.49	64.58	121.24	- -	- -	Free Cash Flow per Basic Share
1.46	1.75	1.75	4.32	2.66	4.74	15.43	7.22	18.2	18.28	36.76	28	35.29	44.29	- -	- -	Dividend per Share
8.76	21.52	38.05	1	1	98.7	144	209.57	242.74	288.23	346.29	450.86	553.49	591.8	591.8	2	Book Value per Share
100.8	125.91	159.23	197	233	224.4	266.76	349.62	382.64	430.49	477.33	585.37	688.55	747.91	856.44	856.44	Tangible Book Value per Share
120	120	120	120	120	120	120	120	120	120	120	120	120	120	- -	120	Basic Weighted Avg Shares
13,439	16,321	19,534	23,181	27,017	37,233	49,577	56,162	63,142	72,658	81,920	87,284	105,120	115,993	126,676	126,676	Sales/Revenue/Turnover
14.58	17.35	19.4	18.49	13.72	10.06	15.55	16.22	14.23	13.05	15.54	19.15	16.68	11.2	15.36	15.36	Operating Margin (%)
234	270	279	360	427	709	1,006	1,012	1,430	1,932	2,528	2,746	3,040	3,104	2,993	2,993	Depreciation Expense
2,351	3,301	4,255	4,961	4,441	3,916	6,731	8,920	6,309	7,605	11,271	15,850	16,456	9,842	17,958	17,958	Net Income, GAAP
4.09	7.07	6.36	2.7	2.42	13.14	19	6.22	31.05	18.96	8.77	12.18	8.89	22.84	10.46	10.46	Effective Tax Rate (%)
17.49	20.22	21.78	21.4	16.44	10.52	13.58	15.88	9.99	10.47	13.76	18.16	15.65	8.48	14.18	14.18	Profit Margin (%)
8,849	17,270	10,985	11,930	9,090	3,321	11,738	12,383	15,319	20,259	22,527	33,248	36,301	50,225	64,170	64,170	Working Capital
695	7,317	1,272	923	539	386	1,235	2,088	1,307	2,313	1,592	342	758	703	2,293	2,293	LT Debt
12,053	15,078	19,055	23,739	27,900	30,847	35,992	45,829	49,853	55,720	63,090	75,580	88,473	94,350	107,144	107,144	Total Equity
- -	12.59	12.65	13.22	9.87	8.01	14.42	17.99	11.05	12.34	16	16.98	15.4	8.99	15.15	15.15	Return on Invested Capital (%)
- -	37.16	32.58	45.56	47.28	25.94	28.26	31.82	18.03	18.44	21.92	23.97	19.63	11.38	21.18	35.13	Return on Capital (%)
- -	182.31	119.46	212.49	3,714.33	65.7	46.39	42.2	23.33	23.96	29.71	33.26	27.41	14.37	25.38	50.59	Return on Common Equity (%)

	Sep'24	Dec'24	Mar'24
Total Current Assets	96,621	- -	104,116
Accounts Receivable, Net	24,478	- -	22,528
Cash, Cash Equivalents & STI	38,350	- -	46,585
Inventories	25,415	- -	26,612
Total Current Liabilities	39,121	- -	39,946
Payables & Accruals	12,327	- -	18,031
ST Debt	12,620	- -	11,892
Deferred Revenue	- -	- -	- -

	Sep'24	Dec'24	Mar'24
ST Debt	12,620	- -	11,892
LT Borrowings	- -	- -	400
LT Finance Leases	1,810	- -	1,893
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	120	120	120
Market Capitalization	422,076	613,793	584,625

Year	Q1	Q2	Q3	Q4	FY
2022	27,314	28,000	26,190	23,617	105,120
2023	25,764	30,794	30,409	29,026	115,993
2024	29,677	34,402	33,239	29,358	126,676